We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Survodutide (BI 456906)
An investigational once-weekly injectable peptide that activates TWO receptors — glucagon and GLP-1 — being developed by Boehringer Ingelheim for obesity and MASH. Honest framing: in a phase-2 dose-finding obesity trial it cut bodyweight ~14.9% at 46 weeks (planned-treatment, top dose), and in a separate phase-2 MASH trial it improved liver histology in up to 62% of participants versus 14% on placebo — genuinely strong phase-2 signals. The first phase-3 read-outs have now landed (SYNCHRONIZE-1 obesity: ~13% weight loss at 76 weeks; SYNCHRONIZE-MASLD: 84% vs 24% achieved ≥30% liver-fat reduction), broadly confirming the phase-2 signals. BUT there are no completed cardiovascular-outcome (SYNCHRONIZE-CVOT) data. It is a prescription-pathway investigational drug, not a dietary supplement, and grey-market 'survodutide' sold online is especially risky.
Prescription medication — not a dietary supplement
Survodutide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Survodutide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2023–2026 with a typical study size of 216 participants.
Based on 33 studies · 5 meta-analyses · 12 RCTs · 982 total participants
Confidence
High confidenceBy outcome
Investigational GLP-1/glucagon dual agonist with strong, consistent phase-2 and now-positive phase-3 RCTs for weight and liver fat, but it has no cardiovascular-outcome data.
10 randomised trials
100% were about Survodutide in an audit of 10 of them
Every randomised or controlled trial of Survodutide indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
11 trials ongoing or recruiting · 18 completed on ClinicalTrials.gov
2 of the completed trials have posted results
Registered trials show research momentum for Survodutide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Survodutide (developmental code BI 456906) is a single synthetic peptide engineered by Boehringer Ingelheim as a balanced dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R).
The mechanistic rationale is to combine two complementary signals: GLP-1 agonism reduces appetite and food intake, slows gastric emptying and enhances glucose-dependent insulin secretion (the axis exploited by semaglutide), while adding glucagon-receptor agonism is intended to increase energy expenditure and mobilise hepatic fat — components a GLP-1 mono-agonist lacks.
Its long half-life supports once-weekly subcutaneous dosing with stepwise escalation to limit gastrointestinal effects. The human evidence to date is genuinely promising but still phase-2-centred.
A randomised, double-blind, placebo-controlled dose-finding phase-2 obesity trial (Lancet Diabetes Endocrinol 2024, n=387) showed dose-dependent weight loss reaching about -14.9% at the 4.8 mg dose at 46 weeks (planned-treatment), versus -2.8% on placebo, with higher loss reported at higher/longer exposure.
A 48-week phase-2 MASH-and-fibrosis trial (NEJM 2024, n=293) met its primary endpoint: histologic MASH improvement without worsening fibrosis occurred in up to 62% (4.8 mg) versus 14% on placebo, with liver-fat reduction of at least 30% in ~57-67% of treated participants and a fibrosis-improvement signal — the first dual GCGR/GLP-1R agent to show this on biopsy.
A phase-2 type-2-diabetes dose-response trial (Diabetologia 2024, n=413, with a semaglutide comparator) showed dose-dependent HbA1c reductions, and a phase-1 study in people with cirrhosis (J Hepatol 2024) characterised pharmacokinetics and tolerability and saw reductions in liver-fat markers and bodyweight.
A 2025 systematic review and meta-analysis (6 RCTs, n=1272) pooled these data: survodutide significantly reduced HbA1c (WMD -0.66%), bodyweight (WMD -6.7 kg) and waist circumference, with effects greater at total weekly doses >2.4 mg and durations >16 weeks. The honest caveats remain substantial.
The first phase-3 efficacy trials have now reported: SYNCHRONIZE-1 (NEJM 2026, n=725) showed ~12-13% weight loss at 76 weeks in obesity without diabetes (below the phase-2 top-dose ~14.9% planned-treatment figure, reflecting the more conservative treatment-regimen estimand), and SYNCHRONIZE-MASLD (Nat Med 2026, n=216) met its co-primary liver-fat and weight endpoints.
But the dedicated cardiovascular-outcomes trial (SYNCHRONIZE-CVOT) is still ongoing, so there are no hard-outcome (cardiovascular/renal/mortality) results to confirm long-term safety.
Adverse effects are class-typical and dose-related gastrointestinal events (nausea, vomiting, diarrhoea were markedly more common than placebo and drove higher discontinuation), and glucagon-receptor agonism is associated with modest heart-rate increases and theoretical hepatic/glucose effects.
Like the GLP-1 class it carries expected concerns about gallbladder events, pancreatitis, lean-mass loss alongside fat loss, and a class thyroid C-cell warning, none yet resolved by long-term human data.
Crucially, unregulated 'survodutide' is already sold grey-market online; using an investigational drug with no clinical oversight, identity/purity guarantee or safety monitoring is especially dangerous.
Because it is a prescription-pathway investigational drug rather than a supplement to recommend, it is sandboxed out of goal-based and stack recommendations here.
Like the approved GLP-1 drugs, survodutide activates the GLP-1 receptor, which reduces appetite and food intake, slows gastric emptying and enhances glucose-dependent insulin secretion. This is the shared incretin backbone driving much of the weight and glycemic effect.
The distinguishing second arm: adding glucagon-receptor agonism is intended to raise energy expenditure and mobilise hepatic fat — components a GLP-1 mono-agonist lacks, and the proposed reason dual agonism may help MASH/liver fibrosis beyond GLP-1 alone. Preclinical work attributes the augmented weight and liver effects specifically to the glucagon (hepatic GCGR) component. Glucagon agonism can also modestly raise heart rate and has theoretical glucose effects.
Survodutide was tuned to a balanced GCGR/GLP-1R potency ratio so the net clinical effect depends on the balance of two signals rather than a single target. The drug acts in part through circumventricular brain regions linked to appetite regulation. This balance — and whether the glucagon arm's metabolic upside outweighs its cardiovascular/glucose risks — is a key uncertainty phase-3 trials are meant to resolve.
How Survodutide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Obtaining or using grey-market 'survodutide' means taking an investigational drug with no clinical oversight, dosing standard, or product-quality guarantee. Strongly discouraged.
High hypoglycemia risk if combined; only relevant under trial-level medical supervision with secretagogue adjustment.
The heart-rate increase and absence of completed cardiovascular-outcome data make unsupervised use particularly unwise.
Contraindicated — not studied; weight-loss pharmacotherapy is avoided in pregnancy.
GLP-1 agonism slows gastric emptying, which can reduce the rate/extent of absorption of co-administered oral drugs — relevant for time-critical or narrow-therapeutic-index oral medicines.
Combining a glucose-lowering incretin agonist with insulin or sulfonylureas increases hypoglycemia risk; dose reduction of the secretagogue is typically required in supervised use.
Stacking survodutide with another GLP-1/incretin agonist compounds gastrointestinal toxicity and glucose-lowering with no evidence of benefit; this combination is not studied and is dangerous.
Tip: Dose-related and markedly more common than placebo; mitigated by a lower starting dose and slow escalation. Drove higher treatment discontinuation in trials.
Tip: Class-typical GI effects; generally transient and dose-related.
Tip: Modest dose-related rise likely linked to glucagon-receptor agonism; long-term cardiovascular significance unknown pending the SYNCHRONIZE-CVOT trial. Requires clinical monitoring.
Tip: Marked appetite suppression; as with the GLP-1 class, part of the weight lost is lean mass — adequate protein and resistance exercise are advised in supervised settings.
Tip: Rapid weight loss and incretin-class effects are associated with gallbladder events; report severe abdominal pain.
Tip: A class concern for incretin drugs; discontinue and seek care for persistent severe abdominal pain. Long-term incidence unknown without phase-3 data.
Survodutide has an evidence score of 5.5/10 — moderate evidence based on 33 indexed studies, including 1 meta-analysis. An investigational once-weekly injectable peptide that activates TWO receptors — glucagon and GLP-1 — being developed by Boehringer Ingelheim for obesity and MASH. Honest framing: in a phase-2 dose-finding obesity trial it cut bodyweight ~14.9% at 46 weeks (planned-treatment, top dose), and in a separate phase-2 MASH trial it improved liver histology in up to 62% of participants versus 14% on placebo — genuinely strong phase-2 signals. The first phase-3 read-outs have now landed (SYNCHRONIZE-1 obesity: ~13% weight loss at 76 weeks; SYNCHRONIZE-MASLD: 84% vs 24% achieved ≥30% liver-fat reduction), broadly confirming the phase-2 signals. BUT there are no completed cardiovascular-outcome (SYNCHRONIZE-CVOT) data. It is a prescription-pathway investigational drug, not a dietary supplement, and grey-market 'survodutide' sold online is especially risky. Representative study: PMID 40922121.
Dosing for Survodutide: SupStack does not provide a self-directed dosing protocol for Survodutide. A dose used in a clinical trial does not establish a safe consumer dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.8-6.0 mg maintenance.
Timing is flexible for Survodutide — consistent daily use matters more than the time of day. Trials dosed once weekly subcutaneously with gradual (often multi-week) dose escalation to limit gastrointestinal effects; the long half-life supports once-weekly administration.
No consumer dose of Survodutide is endorsed, so there is no dose at which it can be called safe. Talk to a healthcare provider before taking it. Reported side effects include pancreatitis, nausea / vomiting, increased heart rate. How often they occur is not established for all of them. Use caution if any of these apply to you: Not a dietary supplement and not an approved drug — investigational; do not self-source grey-market vials; Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell precaution, not a product-label contraindication: this investigational drug has no label, and not every approved GLP-1 product carries the US thyroid boxed warning); History of pancreatitis.
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Orforglipron
Too few graded studiesAn ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity, also studied in type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. In the US, orforglipron is approved as Foundayo for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and increased physical activity. FDA approval was granted on 1 April 2026. An EMA list dated 5 October 2026 places orforglipron under evaluation. Honest appraisal: the phase-2 data are strong and the phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), the US label carries a boxed warning about thyroid C-cell tumours, and long-term outcomes are unsettled. It is NOT a dietary supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 33 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research